Prot# APD356-G000-401: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabete

Project: Research project

Project Details

StatusFinished
Effective start/end date8/7/148/7/20

Funding

  • DrugDev Inc. (Prot #APD356-G000-401)
  • Eisai, Inc. (Prot #APD356-G000-401)